Inhibitory effects of TH2 on human epithelial hepatoma cancer cells

Progress in Biochemistry and Biophysics

Volumn 34, Issue 5, 2007, Pages 503-508

  Xu, Bo ^a   Xing, Cheng ^a   Li, Min ^a   Guo, Wei ^a   Cui, Jing Rong ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Apoptosis; Bel 7402 cell line; p53; Proteasome; TH2

Indexed keywords

GARCINIA;

EID: 34547739477     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Rock K L, Goldberg A L. Degradation of cell proteins and the generation of MHC class I- presented peptides. Annu Rev Immunol, 1999, 17:739-79
2. Unno M, Mizushima T, Morimoto Y, et al. The structure of the mammalian 20S proteasome at 2.75 Å resolution. Structure (Camb), 2002, 10 (5): 609-618
3. Groll M, Ditzel L, Lowe J, et al. Structure of 20S proteasome from yeast at 2.4 A resolution, Nature, 1997, 386 (6624): 463-471
4. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med, 2002, 8 (4 Suppl): S49-54
5. Kisselev A F, Goldberg A L. Proteasome inhibitors: from research tools to drug candidates. Chem Biol, 2001, 8 (8): 739-758
6. Richardson P G, Mitsiades C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Future Oncol, 2005, 1 (2): 161 -171
7. Schmidtke G, Holzhutter H G, Bogyo M, et al. How an inhibitor of the HTV-I protease modulates proteasome activity. J Biol Chem, 1999, 274 (50): 35734-35740
8. Kiyomiya K, Kurebe M, Nakagawa H, et al. The role of the proteasome in apoptosis induced by anthracycline anticancer agents. International J Oncology, 2002, 20 (6): 1205-1209
9. Piccinini M, Tazartes O, Mezzatesta C, et al. Proteasomes are a target of the anti-tumour drug vinblastine. Biochem J, 2001, 356 (Pt 3): 835-841
10. Wang M, Feng X, Zhao Y Y, et al. Chinese Wild Plant Resourse, 2003, 22(1): 1-3
11. Lei Q M, Liu J M. Jiangxi Med, 1982, 3:1 -5
12. Lei Q M, Liu J M. China J Cancer Prev Treat, 2003, 10 (2): 216-219
13. Wu Z Q, Guo Q L, You Q D, et al. Growth inhibitory effect of GGAs on experimental timor in mice and human cell cultured in vitro. Chin J Nat Med, 2003, 1 (2): 99-102
14. Xu B, Monsarrat B, Gairin J E, et al. Effect of ajoene, a natural antitumor small molecule, on human 20S proteasome activity in vitro and in human leukemic HL60 cells. Fundam Clin Pharmacol, 2004, 18 (2): 171-180
15. Guo Q L, You Q D, Wu Z Q, et al. General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice. Acta Pharmacologica Sinica, 2004, 25 (6): 769-774
16. Guo Q L, Lin S S, You Q D, et al. Inhibition of human telomerase reverse transcriptase gene expression by gambogic acid in human hepatoma SMMC-7721 cells. Life Sciences, 2006, 78 (11): 1238-1245
17. Almond J B, Cohen G M. The proteasome: a novel target for cancer chemotherapy. Leukemia, 2002, 16 (4): 433-443
18. Myung J, Kim K B, Lindsten K, et al. Lack of proteasome active site allostery as revealed by subunit- specific inhibitors. Mol Cell, 2001, 7 (2): 411-420
19. Vinitsky A, Michaud C, Powers J C, et al. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry, 1992,31 (39): 9421-9428
20. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. Embo J, 1998, 17 (24): 7151-7160
21. Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Comm, 2005, 331 (3): 851-858
22. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Seminar in Cancer Biology, 2003, 13 (1): 49-58
23. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 2003, 101 (4): 1530-1534